Preferred Label : eribulin;

MeSH note : a halichondrin B derivative that suppresses microtubule growth and acts as an antimitotic agent; structure in first source;

CISMeF synonym : B1793 cpd; B1939 cpd; E7389 cpd; B 1793; B 1939; E 7389; ER-086526; NSC 707389; eribulin mesylate; halaven; eisai brand of eribulin mesylate;

MeSH synonym : 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one;

MeSH hyponym : E-7389; ER086526; ER 086526; ER-86526; NSC707389; NSC-707389; B-1793; B-1939; eribulin monomethanesulfonate; eribulin mesilate; eribulin (as mesylate);

MeSH CAS label : 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one;

MeSH Related Number : AV9U0660CW;

Is substance : O;

UNII : LR24G6354G;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/mevlyq
2024
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
drug approval
europe
eribulin
eribulin
drugs, generic

---
https://www.has-sante.fr/portail/jcms/c_2886957/fr/halaven
2018
false
false
false
France
eribulin mesylate
breast neoplasms
treatment outcome
neoplasm metastasis
injections, intravenous
antineoplastic agents
eribulin
evaluation of the transparency committee
halaven
eribulin
furans
ketones
eribulin
furans
ketones

---
http://www.has-sante.fr/portail/jcms/c_2761874/fr/halaven
https://www.has-sante.fr/portail/jcms/c_2761874/fr/halaven-eribuline-antineoplasique
2017
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
eribulin mesylate
eribulin mesylate
liposarcoma
Unresectable Malignant Neoplasm
Advanced Malignant Neoplasm
neoplasm metastasis
injections, intravenous
eribulin
antineoplastic agents
antineoplastic agents
survival analysis
eribulin
eribulin
furans
ketones
furans
ketones

---
http://www.has-sante.fr/portail/jcms/c_2559139/fr/halaven
http://www.has-sante.fr/portail/jcms/c_2559139/fr/halaven-eribuline-antineoplasique
2015
false
France
French
evaluation of the transparency committee
locally advanced breast cancer
Locally Advanced Malignant Neoplasm
Stage IV Breast Cancer AJCC v6 and v7
guidelines for drug use
eribulin mesylate
furans
ketones
mesylates
eribulin
antineoplastic agents
eribulin
breast neoplasms
neoplasm metastasis
injections, intravenous
treatment outcome
survival analysis

---
Summary Basis of Decision (SBD) for Halaven
Eribulin mesylate, 0.5 mg/mL, Solution, Intravenous injection
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00068
2012
false
Canada
English
French
drug information
furans
furans
ketones
ketones
eribulin
eribulin
eribulin mesylate
eribulin mesylate
eribulin
antineoplastic agents
antineoplastic agents
injections, intravenous
canada
drug approval
breast neoplasms
neoplasm metastasis
treatment outcome
tubulin modulators
tubulin modulators

---
https://www.ema.europa.eu/medicines/human/EPAR/Halaven
2012
United Kingdom
French
English
syndication feed
eribulin mesylate
eribulin mesylate
mesylates
ketones
ketones
furans
furans
mesylates
eribulin
breast neoplasms
neoplasm metastasis
injections, intravenous
tubulin modulators
tubulin modulators
treatment outcome
drug interactions
pregnancy
breast feeding
fertility
halichondrin B
survival analysis
drug evaluation, preclinical
ethers, cyclic
eribulin
eribulin
summary of product characteristics
package leaflet
drug evaluation

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63816522
2012
France
package leaflet
summary of product characteristics
eribulin
injections
eribulin mesylate

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-09/halaven_-_ct10752.pdf
http://www.has-sante.fr/portail/jcms/c_1096739/halaven
2011
France
French
evaluation of the transparency committee
eribulin mesylate
furans
ketones
mesylates
eribulin
antineoplastic agents
eribulin
breast neoplasms
neoplasm metastasis
injections, intravenous
treatment outcome
survival analysis

---
http://www.has-sante.fr/portail/jcms/c_1191640/halaven-eribuline-antineoplasique
http://www.has-sante.fr/portail/jcms/c_1191622/halaven-20072011synthese-ct10752
http://www.has-sante.fr/portail/jcms/c_1099359/halaven-ct10752
2011
France
French
eribulin mesylate
breast neoplasms
neoplasm metastasis
eribulin
antineoplastic agents
halichondrin B
eribulin
injections, intravenous
treatment outcome
clinical trials as topic
disease-free survival
survival analysis
ethers, cyclic
furans
ketones
mesylates
evaluation of the transparency committee
guidelines for drug use

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.